Next Phase Newsletter

A venture capital arm of a global conglomerate has several global offices including two sites in the US. In 2021, the firm raised a dedicated life science fund to invest in therapeutic and bioprocessing companies with flexibility of entering at different stages of development. The investment size varies depending on the opportunity. The firm is actively seeking new investment opportunities globally.

The firm will make new investments from both traditional funds and their new life science fund. The traditional funds invest in customer-centered health strategies, which may include mobile health IT, digital health, and artificial intelligence applied to healthcare. The new life science fund is interested in therapeutics, particularly gene therapy, ADC technologies, RNA delivery platform technologies, and bioprocessing business that support these strategic areas of interest.

The firm primarily invests in life science companies with a strong and experienced management team. The firm usually takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2012 and headquartered in the US invests in life science, tech, and healthcare companies at Series A and B stages. The firm requires their portfolio companies to have at least one woman in the founding team. Typical check size is USD $1M-3M. The firm is open to investing in global companies, however, the companies need to have some presence in the U.S. as well. The firm usually acts as a co-investor.

The firm’s premise is frontier technology and medical breakthrough. The firm invests in a wide range of life science sectors including therapeutics, diagnostics, and digital health. The firm has invested in hardware, AI in drug discovery, gene editing, and more. The firm is indication-agnostic and will look at companies in all stages of development, though most are earlier.

The firm requires portfolio companies to have at least one woman on the founding team. The firm may not take a board seat on a case-by-case basis as the firm likes to maintain strong relationships with founders and advise in an informal setting.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm based in the US is focused on early-stage health technology investments with a consumer-focus. The firm is looking for companies with solutions that drive consumer engagement and health accountability (these do not have to sell D2C, most of their companies do not). Through the firm’s latest fund, the firm will focus on investing in early-stage, consumer-centric digital health technologies. The firm’s initial investments generally range from $1,000,000 to $5,000,000. The firm is primarily thesis-focused and invests from Seed to Series B, with a focus just at or before the A round.

The firm is seeking digital health companies focused on the empowering consumers to be better stewards of their health and their healthcare expenditures. Accordingly, the firm is not interested in technology that solve problems solely within payers and providers, such as billing, care coordination for hospitals, or EHR platforms. The firm is indication agnostic, though has interest in chronic illnesses, social determinants, behavioral health, and personalized care among others.

The firm does not have set management team requirements. The firm will play a very active role post-investment, traditionally by taking board seats, providing key sales introductions, assisting with scaling, hiring, and providing network support.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A life sciences investment firm with a focus on supporting emerging biotechnology companies closed a new fund in 2022 dedicated to private investments. The firm focuses exclusively in biopharmaceuticals and looks to make Seed through Series B investments with a typical check size averaging $10M. The firm typically makes investments in the form of equity but will do convertible notes for some Seed stage investments. The firm looks to make investments in the US and Europe.

The firm invests exclusively in therapeutics but is subsector and indication agnostic and open all modalities with a particular focus in cell therapy, RNA therapy, small molecules and antibodies. The firm is open to preclinical companies.

The firm looks for established management teams with the CEO in place. The firm likes to see teams that are credible but don’t necessarily need prior experience starting a company. The firm likes to follow teams as they advance. The firm is open to both leading and coinvesting and seeks a board seat in either circumstance.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in China with over US$9.5 billion in total managed assets in the areas of technology and consumer (T&C) and healthcare has offices located in Shanghai, Beijing, Suzhou and Hong Kong. In China, the firm has invested in over 200 healthcare companies, that span most sectors of life sciences from innovative drugs, medical devices, diagnostics, and healthcare services. The firm invests primarily in US and China-based companies.

The firm is open to many sectors in the life science space – innovative drugs, medical devices, diagnostics, and healthcare services. The firm is most interested in breakthrough products and technologies that address a large unmet need. The firm is also interested in enabling technologies for drug discovery and development, and other healthcare-related technologies in the “digital-health” space.

The firm is seeking to invest in companies with novel ideas and technology and experienced and passionate management. The firm’s team is “hands-on” and typically assumes a board seat after an investment. In general, the firm invests globally and prefers companies that have upside opportunities in China and can leverage the firm’s China network and expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm based in the US is focused on companies in the healthcare field with a preference for innovative technology-based companies in Medtech, Diagnostics, and Digital Health. For medical devices, the firm will invest in both PMA and 510k devices and prefers to see some clinical validation. The firm is stage agnostic but most often first invests $3-8M in Series A-C and reserves funds for follow-on investments. Most of the firm’s investments have been in the US and Israel, but the firm is open to investing globally.

The firm invests in companies with medical device, diagnostics and digital health technologies, focusing on innovative companies that can revolutionize their space. The firm favors technology-based products, such as genomics-based diagnostics or high-tech medical devices. Within digital health, the firm is fairly open, but has an interest in companies developing tools for clinical trials and other products developed for payer networks or Big Pharma. The firm is also interested in digital health technologies for hard-to-reach patient populations, such as those suffering from mental health disorders or substance abuse. While fairly opportunistic with regards to indication, the firm is particularly interested in technologies in the COPD, pulmonary hypertension, orthopedic and neurological space as well as products using ablation to treat pain.

The firm wants to see a strong CEO and Board when making investments. While often a not a lead investor, the firm is very active and will frequently take a Board seat after investing. The firm is looking to lead more investments when investing from their third fund.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A private investment firm based in the US launched a fund about 10 years ago to invest in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

The firm focuses on early-stage digital health projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; that provide more meaningful tracking of health metrics for patients (health and wellness analytics); or initiatives at the intersection of molecular diagnostics and bioinformatics that comb genetic blueprints for clinically-relevant patterns (precision medicine).

The firm is an active and engaged investor, and can act as either a lead or co-investor. The firm prefers to lead investments in seed rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.